within Pharmacolibrary.Drugs.ATC.C;

model C10AX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 4.1666666666666667e-07,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006666666666666666,
    Tlag           = 600
  );
  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>MagnesiumPyridoxal5PhosphateGlutamate</td></tr><tr><td>ATC code:</td><td>C10AX07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>25</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.5</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Magnesium pyridoxal 5-phosphate glutamate is a combination medication containing a magnesium salt of pyridoxal 5-phosphate (an active form of vitamin B6) with glutamate. It has been used in some countries for the treatment of hyperlipidemia and to support cardiovascular health. It is not approved in the United States and has limited or no current widespread clinical use.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data in humans; the following are crude estimates based on closely related compounds (magnesium salts, B6 derivatives, glutamate) in healthy adults.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end C10AX07;
